UPDATE: Medtronic, First Patient Enrolled Into European Registry for Deep Brain Stimulation in Patients With Refractory Epilepsy

Medtronic, Inc. MDT today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy. DBS for epilepsy received CE mark for use in Europe in August 2010. Medtronic DBS Therapy is not currently approved by the U.S. Food and Drug Administration for use in the United States for the treatment of refractory epilepsy. The MORE Registry will involve approximately 200 prospective patients over two years from more than 30 centres across Europe including the Tampere and Tubingen Hospitals which have the most experience to date with DBS of the Anterior Nucleus of the Thalamus. The primary objective of the registry is to examine the impact of DBS therapy on seizure frequency. The study will also look at seizure type and severity, safety and impact of the therapy on a patient's quality of life.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsM&AGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!